Yuki Takaoka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yuki Takaoka has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Shioya
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada, Japan
1 shared publication - Hiroyuki Tsuji
Departments of Head & Neck Surgery, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan
1 shared publication - Jia Han
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan
1 shared publication - Morimasa Kitamura
Departments of Head & Neck Surgery, Kanazawa Medical University Hospital, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan
1 shared publication - Sohsuke Yamada
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Uchinada 920-0293, Ishikawa, Japan
1 shared publication - Xin Guo
Hebei Key Laboratory of Turbidity Toxin Syndrome, Shijiazhuang 050011, China
1 shared publication
Latest Publications
- Open Access
- 17 March 2022
- Published by MDPI AG in Endocrines
- Vol. 3 (1) , 139-149
PRDX4 Potentially Predicts the Postoperative Outcome in Advanced Papillary Thyroid Carcinoma
Background: Peroxiredoxin 4 (PRDX4), a secreted antioxidant enzyme, can protect against hepatocellular carcinoma and lung adenocarcinoma, but its role in papillary thyroid carcinoma (PTC) is still unclear. In this study, we investigated the association of the PRDX4 expression with the prognosis of patients with advanced PTC. Methods: We conducted a retrospective case-control study at Kanazawa Medical University Hospital. We selected PTC patients over 55 years of age who received surgery from 2006 to 2014. The PRDX4 expression was immunohistochemically analyzed in paraffin-embedded tumor specimens of 70 patients with stages Ⅱ–Ⅳ advanced PTC. We also investigated the key roles of PRDX4 in a human PTC cell line (K-1) in vitro. Result: The weak expression of PRDX4 was found to be significantly associated with recurrence. In a multivariate analysis, the weak expression of PRDX4—rather than other pathological features of high invasiveness—predicted a poor prognosis. In vitro, the viability of human PTC cells was significantly suppressed after PRXD4 plasmid transfection. Conclusion: The weak expression of PRDX4 can predict recurrence with a potential poor prognosis in advanced PTC.
- 17 March 2022
- Published by MDPI AG in Endocrines
- Vol. 3 (1) , 139-149
Open AccessPRDX4 Potentially Predicts the Postoperative Outcome in Advanced Papillary Thyroid Carcinoma
Background: Peroxiredoxin 4 (PRDX4), a secreted antioxidant enzyme, can protect against hepatocellular carcinoma and lung adenocarcinoma, but its role in papillary thyroid carcinoma (PTC) is still unclear. In this study, we investigated the association of the PRDX4 expression with the prognosis of patients with advanced PTC. Methods: We conducted a retrospective case-control study at Kanazawa Medical University Hospital. We selected PTC patients over 55 years of age who received surgery from 2006 to 2014. The PRDX4 expression was immunohistochemically analyzed in paraffin-embedded tumor specimens of 70 patients with stages Ⅱ–Ⅳ advanced PTC. We also investigated the key roles of PRDX4 in a human PTC cell line (K-1) in vitro. Result: The weak expression of PRDX4 was found to be significantly associated with recurrence. In a multivariate analysis, the weak expression of PRDX4—rather than other pathological features of high invasiveness—predicted a poor prognosis. In vitro, the viability of human PTC cells was significantly suppressed after PRXD4 plasmid transfection. Conclusion: The weak expression of PRDX4 can predict recurrence with a potential poor prognosis in advanced PTC.